摘要
目的:探讨克癌新对荷瘤小鼠肿瘤生长及免疫功能的影响。方法:建立小鼠肉瘤S180及小鼠肝癌H22移植性肿瘤模型,观察克癌新对荷瘤小鼠肿瘤生长的抑制作用;采用腹腔巨噬细胞吞噬试验、淋巴细胞转化试验及E lisa法测定细胞因子IL-2和IL-6的水平,探讨克癌新对荷瘤小鼠免疫功能的影响。结果:克癌新在150和300 mg.kg-1时对小鼠肉瘤S180的生长抑制率分别为38.52%和47.88%,对肝癌H22生长抑制率分别为32.17%和40.18%,且能提高荷瘤小鼠的脾指数和胸腺指数;克癌新能增强荷瘤小鼠腹腔巨噬细胞的吞噬功能,促进淋巴细胞转化反应,升高荷瘤小鼠细胞因子IL-2和IL-6的水平。结论:克癌新有较强的体内抗肿瘤活性,其抗肿瘤机制可能与增强机体免疫功能有关。
Objective : To determine the effect of Keaixin on the tumor growth and immune ruction in tumor- bearing mice. Methods : Antitumor activity of Keaixin in vivo was observed in mice bearing tumors of H22 and S180. The effect of Keaixin on immune function in tumor-bearing mice was evaluated by phagocytosis test, T plymphocyte proliferation test, and ELISA for IL-2 and IL-6. Results: At 150 and 300 mg· kg^-1 , Keaixin inhibited tumor growth by 38.52% and 47.88% in S180-bearing mice, and by 32.17% and 40.18% in H22-bearing mice, respectively. Keaixin increased spleen index and thymus gland index, improve the phagocytosis function of macrophages, enhanced the T lymphocyte proliferation, and increased the expression levels of IL-2 and IL-6. Conclusion: Keaixin exhibits an anti-tumor effect in vivo and enhances immune function in tumor-bearing mice.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2008年第23期2027-2030,共4页
Chinese Journal of New Drugs